LL-37 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

LL-37

Also known as: hCAP18/LL-37, human cathelicidin, CAMP peptide, cathelicidin antimicrobial peptide, CRAMP (murine ortholog)

Human cathelicidin antimicrobial peptide (AMP); host defense peptide

Research chemicalLast updated: October 19, 2026Based on 41 peer-reviewed studies

What it is

LL-37 is a natural antimicrobial peptide the body produces as part of its immune defense, studied for its ability to fight bacteria, viruses, and fungi, and to accelerate wound healing. It works by directly disrupting microbial membranes and activating immune responses. No FDA-approved therapeutic use; active area of clinical research.

The scientific side

LL-37 is the sole human cathelicidin, encoded by the CAMP gene as the precursor hCAP18 and proteolytically cleaved extracellularly to its active form. It exerts broad-spectrum antimicrobial activity against bacteria, fungi, viruses, and parasites through multiple mechanisms including membrane disruption, pore formation, biofilm inhibition, and interference with viral entry and replication. Against bacteria, these mechanisms include cell wall destruction, membrane permeabilization, oxidative stress induction, quorum-sensing suppression, and biofilm matrix degradation. Against SARS-CoV-2, LL-37 binds the Spike protein S2 subunit and accessory proteins ORF7a and ORF8, inhibiting TMPRSS2-mediated priming and membrane fusion, as well as blocking ACE2 receptor interaction. LL-37 also acts as an immunomodulator with both pro- and anti-inflammatory effects: it promotes chemotaxis of immune cells, modulates apoptosis (proapoptotic or antiapoptotic depending on cell type and concentration), activates mast cells via MrgX2 and other receptors, promotes neutrophil extracellular trap (NET) formation, regulates autophagy, and modulates signaling pathways including NF-κB, Akt, MAPK/ERK, Wnt/β-catenin, and NLRP3 inflammasome pathways. It promotes wound healing, angiogenesis, and tissue repair. Vitamin D upregulates CAMP gene expression and hCAP18/LL-37 protein production. LL-37 is cytotoxic to many human cell types at concentrations of 1–10 µM.

Class: Human cathelicidin antimicrobial peptide (AMP); host defense peptide

Administration & storage

Administration
Intratracheal administration (in mice; PMID: 38310763)Intravenous bolus (in mice~20 µg gallium-67 labeled variant; PMID: 38972467)Subcutaneous administration (in mice~20 µg gallium-67 labeled variant; PMID: 38972467)Topical cream (twice weekly in humans with diabetic foot ulcer; PMID: 37480520)In vitro cell treatment (multiple PMIDs)
Storage
No storage conditions for LL-37 are reported in the reviewed abstracts.
Cautions
LL-37 is cytotoxic to many human cell types at final concentrations of 1–10 µM in vitro; very high concentrations (300 µM) are detected in psoriatic lesions, implying potential host cell toxicity at sites of inflammation.,LL-37 is highly susceptible to proteolytic degradation in vivo, limiting its stability and half-life; this is a recognized barrier to therapeutic application (PMID: 41270816, PMID: 11000000).,Elevated LL-37 levels have been associated with hypercoagulation in COVID-19 patients, with cathelicidin injection promoting thrombosis in animal models.,LL-37 may exacerbate pro-inflammatory responses at high concentrations, e.g., via FPR2 in periodontitis and via TLR4-NF-κB-NLRP3 in Kawasaki disease coronary endothelial cells.,No human pharmacokinetic data for injected/systemic LL-37 administration are available from the reviewed literature; preclinical biodistribution data only. Sterile technique is essential for any parenteral preparation.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification